In the broad spectrum of Lu AA-33810, we find endless perspectives, approaches and interpretations that invite us to immerse ourselves in its richness and complexity. Throughout history, Lu AA-33810 has played a fundamental role in people's lives, influencing the way we relate, think and create. From its origins to its impact on today's society, Lu AA-33810 has been the object of study, admiration and debate, generating endless reflections and arguments that seek to understand and value its importance. In this article, we will explore different facets of Lu AA-33810, exploring its meaning, evolution and relevance in our world today.
| Clinical data | |
|---|---|
| Other names | Lu AA-33810 |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H25N3O2S3 |
| Molar mass | 423.61 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Lu AA-33810 is a drug developed by Lundbeck, which acts as a potent and highly selective antagonist for the neuropeptide Y receptor Y5, with a Ki of 1.5nM and around 3300x selectivity over the related Y1, Y2 and Y4 receptors. In animal studies it produced anorectic, antidepressant and anxiolytic effects, and further research is now being conducted into its possible medical application in the treatment of eating disorders.[1]